醒脑静注射液对急性脑梗死血瘀证患者疗效及相关指标的影响

发布时间：2019-03-09 10:23

【摘要】：目的:探讨醒脑静注射液对急性脑梗死血瘀证患者疗效及相关指标的影响。方法:70例急性脑梗死血瘀证患者随机分为对照组(35例)和观察组(35例)。对照组患者按照《中国急性缺血性脑卒中诊治指南(2014)》常规治疗,在溶栓时间窗内静脉输注重组人组织型纤溶酶原激活剂,超过溶栓时间窗者每晚口服拜阿司匹林肠溶片0.3 g,1周后改为每晚0.1 g+每晚口服阿托伐他汀钙片40 mg,如患者存在吞咽困难可经胃管给药。观察组患者在对照组治疗的基础上给予醒脑静注射液30 ml加入0.9%氯化钠注射液250 ml中静脉滴注,每日1次。两组疗程均为14 d。观察两组患者的临床疗效,治疗前后的γ干扰素(IFN-γ)、白细胞介素(IL)-13、IL-4、超敏C反应蛋白(hs-CRP)水平,美国国立卫生院卒中量表(NIHSS)评分、改良Barthel(BI)指数评分、脑梗死体积及不良反应发生情况。结果:两组患者总有效率、不良反应发生率比较,差异均无统计学意义(P0.05)。治疗前,两组患者IFN-γ、IL-13、IL-4、hs-CRP水平及NIHSS评分、BI指数评分、脑梗死体积比较,差异均无统计学意义(P0.05);治疗后,两组患者IFN-γ、hs-CRP水平及NIHSS评分、脑梗死体积均显著低于同组治疗前,且观察组低于对照组,IL-13、IL-4水平及BI指数评分均显著高于同组治疗前,且观察组高于对照组,差异均有统计学意义(P0.05或P0.01)。结论:在常规治疗的基础上,醒脑静注射液治疗急性脑梗死血瘀证的疗效显著,可降低患者炎症因子水平,改善其神经功能缺损、日常生活能力及脑梗死体积,且安全性较好。
[Abstract]:Objective: To study the effect of Xingnaojing injection on the curative effect and related indexes of the patients with acute cerebral infarction and blood stasis syndrome. Methods:70 patients with acute cerebral infarction and blood stasis were randomly divided into control group (35 cases) and observation group (35 cases). In the control group, according to the guidelines for diagnosis and treatment of acute ischemic stroke in China (2014)> routine treatment, the recombinant human tissue type plasminogen activator was infused intravenously in the time window of the thrombolysis, and 0.3 g of aspirin enteric coated tablets were orally taken per night for the time window of the thrombolytic time. After 1 week, an oral dose of 40 mg of atorvastatin calcium tablet was orally taken at 0.1 g/ night per night, for example, if the patient had a dysphagia that could be administered by a gastric tube. On the basis of the treatment of the control group, the observation group received 30 ml of Xingnaojing injection, and then added with 0.9% sodium chloride injection 250ml for intravenous drip, once a day. The clinical efficacy of the two groups was observed, and the clinical efficacy of the two groups was observed. The levels of interferon (IFN-1), interleukin (IL)-13, IL-4, hypersensitive C-reactive protein (hs-CRP), and the score of the National Center for Stroke Scale (NIHSS) of the National Health Center of the United States were improved, and the Barthel (BI) index score was improved. The volume of cerebral infarction and the occurrence of adverse reaction. Results: The total effective rate and adverse reaction rate of the two groups were not statistically significant (P0.05). The levels of IFN-1, IL-13, IL-4, hs-CRP and NIHSS in the two groups were not significant (P0.05). After the treatment, the levels of IFN-1, hs-CRP and NIHSS in the two groups were significantly lower than that of the same group. The levels of IL-13, IL-4 and BI in the observation group were significantly higher than those in the control group, and the observation group was higher than that in the control group (P0.05 or P0.01). Conclusion: On the basis of routine treatment, Xingnaojing injection is effective in the treatment of acute cerebral infarction and blood stasis syndrome, can lower the level of inflammatory factor of the patient, improve the neurological function defect, the daily life ability and the volume of cerebral infarction, and has good safety.
【作者单位】：荆门市第一人民医院;荆楚理工学院医学院;荆楚理工学院图书馆;
【基金】：湖北省教育厅科学研究计划项目(No.Q20144303) 荆门市科技计划重点项目(No.荆科计〔2014〕7号) 荆楚理工学院校级科研基金项目(No.ZR201404)
【分类号】：R743.3

【相似文献】